Maxim Group analyst Jason McCarthy maintained a Buy rating on CNS Pharmaceuticals (CNSP – Research Report) on August 27 and set a price target of $4.00. The company’s shares closed last Monday at $1.66, close to its 52-week low of $1.39.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 18.6% and a 36.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Appili Therapeutics Inc Class A, and Brainstorm Cell Therapeutics.
CNS Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $4.00, which is a 143.9% upside from current levels. In a report issued on August 27, Alliance Global Partners also initiated coverage with a Buy rating on the stock with a $4.00 price target.
The company has a one-year high of $4.46 and a one-year low of $1.39. Currently, CNS Pharmaceuticals has an average volume of 495.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Read More on CNSP: